Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 2
1986 3
1987 4
1988 2
1989 7
1990 6
1991 8
1992 8
1993 3
1994 1
1995 4
1996 8
1997 6
1998 5
1999 5
2000 5
2001 5
2002 7
2003 2
2004 8
2005 6
2006 7
2007 9
2008 9
2009 15
2010 23
2011 14
2012 16
2013 17
2014 16
2015 26
2016 20
2017 18
2018 12
2019 11
2020 8
2021 9
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Results by year

Filters applied: . Clear all
Page 1
Genomic imbalances analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
Balducci E, Simonin M, Duployez N, Steimlé T, Dourthe ME, Villarese P, Ducassou S, Arnoux I, Cayuela JM, Balsat M, Courtois L, Andrieu GP, Touzart A, Huguet F, Petit A, Ifrah N, Dombret H, Baruchel A, Macintyre EA, Preudhomme C, Boissel N, Asnafi V. Balducci E, et al. Among authors: ifrah n. Blood. 2024 Mar 22:blood.2023022154. doi: 10.1182/blood.2023022154. Online ahead of print. Blood. 2024. PMID: 38518104
[Cancers in France: 10 key messages].
Ifrah N, Méric JB, Bousquet PJ. Ifrah N, et al. Rev Prat. 2024 Jan;74(1):52. Rev Prat. 2024. PMID: 38329253 French. No abstract available.
TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2.
Balducci E, Steimlé T, Smith C, Villarese P, Feroul M, Payet-Bornet D, Kaltenbach S, Couronné L, Lhermitte L, Touzart A, Dourthe ME, Simonin M, Baruchel A, Dombret H, Ifrah N, Boissel N, Nadel B, Macintyre E, Cieslak A, Asnafi V. Balducci E, et al. Among authors: ifrah n. Mol Cancer. 2023 Jul 10;22(1):108. doi: 10.1186/s12943-023-01794-y. Mol Cancer. 2023. PMID: 37430263 Free PMC article.
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study.
Orvain C, Chantepie S, Thomas X, Escofrre-Barbe M, Huguet F, Desbrosses Y, Guillerm G, Uzunov M, Leguay T, Barbieux S, Vey N, Chevallier P, Malfuson JV, Lepretre S, Baumann M, Aykut M, Chaib A, Joris M, Zerazhi H, Stussi G, Chapiro J, Berthon C, Bonmati C, Jourdan E, Carp D, Marcais AR, Gallego-Hernanz MP, Vaida I, Bilger K, Villate A, Pasquier F, Chalandon Y, Maury S, Lheritier V, Ifrah N, Dombret H, Boissel N, Hunault-Berger M. Orvain C, et al. Among authors: ifrah n. Haematologica. 2023 Dec 1;108(12):3287-3297. doi: 10.3324/haematol.2022.282332. Haematologica. 2023. PMID: 36891751 Free PMC article. Clinical Trial.
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Smith C, et al. Among authors: ifrah n. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. Mol Cancer. 2023. PMID: 36650499 Free PMC article.
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.
Drevin G, Briet M, Bazzoli C, Gyan E, Schmidt A, Dombret H, Orvain C, Giltat A, Recher C, Ifrah N, Guardiola P, Hunault-Berger M, Abbara C. Drevin G, et al. Among authors: ifrah n. Pharmaceutics. 2022 Apr 5;14(4):792. doi: 10.3390/pharmaceutics14040792. Pharmaceutics. 2022. PMID: 35456626 Free PMC article.
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins.
Steimlé T, Dourthe ME, Alcantara M, Touzart A, Simonin M, Mondesir J, Lhermitte L, Bond J, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Balsat M, Vey N, Macintyre E, Ifrah N, Dombret H, Petit A, Baruchel A, Ruminy P, Boissel N, Asnafi V. Steimlé T, et al. Among authors: ifrah n. Blood Cancer J. 2022 Jan 26;12(1):14. doi: 10.1038/s41408-022-00613-9. Blood Cancer J. 2022. PMID: 35082269 Free PMC article.
Editorial.
Ifrah N. Ifrah N. Cancer Radiother. 2022 Feb-Apr;26(1-2):1. doi: 10.1016/j.canrad.2021.08.008. Epub 2021 Dec 22. Cancer Radiother. 2022. PMID: 34953700 No abstract available.
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup.
Touzart A, Mayakonda A, Smith C, Hey J, Toth R, Cieslak A, Andrieu GP, Tran Quang C, Latiri M, Ghysdael J, Spicuglia S, Dombret H, Ifrah N, Macintyre E, Lutsik P, Boissel N, Plass C, Asnafi V. Touzart A, et al. Among authors: ifrah n. Sci Transl Med. 2021 May 26;13(595):eabc4834. doi: 10.1126/scitranslmed.abc4834. Sci Transl Med. 2021. PMID: 34039737 Free article. Clinical Trial.
302 results